NFL Hall of Famer Michael Strahan's 19-year-old daughter is fighting cancer:'I don ’t know what I would do without her '
The 19-year-old daughter of NFL Hall of Famer and “Good Morning America” co-anchor Michael Strahan is undergoing treatment for brain cancer. Isabella Strahan appeared on a prerecorded videotape segment sitting next to her father while discussing her diagnosis of medulloblastoma, a cancerous brain…#nflhalloffamer #goodmorningamerica #michaelstrahan #isabellastrahan #robinroberts #southerncal #dukeuniversity #duke #newyorkgiants #superbowl (Source: Reuters: Health)
Source: Reuters: Health - January 12, 2024 Category: Consumer Health News Source Type: news
What are medulloblastomas? As Michael Strahan's daughter Isabella, 19, is diagnosed with brain cancer
Michael Strahan's daughter Isabella revealed that she has been fighting the brain cancer medulloblastoma. Though rare, it's the most common form of brain cancer in children. (Source: the Mail online | Health)
Source: the Mail online | Health - January 11, 2024 Category: Consumer Health News Source Type: news
Stephanie Bissonnette, Cast Member of ‘Mean Girls the Musical,’ Dies at 32
Stephanie Bissonnette, a dancer and choreographer featured in the Broadway musical “Mean Girls the Musical,” has died at 32, the show announced on Twitter on Monday. Bissonnette had been diagnosed in 2019 with medulloblastoma, a rare form of brain cancer that is most commonly found in children.…#meangirlsmusical #ensemble #stephanies #twitter #newyorkcity #stephanie #broadway #broadwaybares #stephaniebissonnette #dawnsweitzer (Source: Reuters: Health)
Source: Reuters: Health - December 20, 2022 Category: Consumer Health News Source Type: news
Radiological Case: Medulloblastoma Radiological Case: Medulloblastoma
Review the imaging findings and pathophysiology of medulloblastoma in this case of a toddler who presented with vomiting and a bulging anterior fontanelle.Applied Radiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 3, 2022 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news
More Children With High-Risk Brain Cancer Now Surviving More Children With High-Risk Brain Cancer Now Surviving
A practice-changing study shows that molecular testing to distinguish medulloblastoma subtypes has significantly improved survival for children with a high-risk subtype.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 26, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Carboplatin Intensification Beneficial for Group 3 Medulloblastoma
Therapy intensification with carboplatin improved five - year event - free survival in children with high - risk group 3 medulloblastoma only (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 23, 2021 Category: Cancer & Oncology Tags: Neurology, Oncology, Pediatrics, Pharmacy, Radiology, Journal, Source Type: news
Carboplatin Intensification Beneficial for Group 3 Medulloblastoma
FRIDAY, July 23, 2021 -- For children with high-risk group 3 medulloblastoma, therapy intensification with carboplatin improves event-free survival, according to a study published online July 22 in JAMA Oncology.
Sarah E. S. Leary, M.D., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 23, 2021 Category: Pharmaceuticals Source Type: news
New generation anti-cancer drug shows promise for children with brain tumors
(Walter and Eliza Hall Institute) A genetic map of an aggressive childhood brain tumour called medulloblastoma has helped researchers identify a new generation anti-cancer drug that can be repurposed as an effective treatment for the disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2021 Category: Cancer & Oncology Source Type: news
Cancer neuroscientists identify a key culprit behind pediatric brain cancer's spread
(Keck School of Medicine of USC) Although rare, medulloblastoma is the most common and deadliest form of pediatric brain cancer. Metastasis to the lining of the brain or spinal cord is responsible for virtually all deaths. New USC research shines a light on how medulloblastoma spreads and may provide clues to new strategies for targeting deadly medulloblastoma metastases. An enzyme called GABA transaminase (ABAT) aids metastases in surviving the hostile environment around the brain and spinal cord and in resisting treatment. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 29, 2021 Category: International Medicine & Public Health Source Type: news
Searching for the cell of origin of childhood brain cancer
(Universit à di Trento) Promising findings from a study coordinated by a research team of the University of Trento on medulloblastoma, the most common malignant brain tumor in children affecting the central nervous system. For the first time, scientists have grown organoids in the laboratory to simulate tumor tissue, and have identified the type of cell from which the tumor may originate. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news
Study sheds light on treatment options for devastating childhood brain cancer
(Washington University School of Medicine) Research from Washington University School of Medicine in St. Louis suggests that children with average risk medulloblastoma can receive radiation to a smaller volume of the brain at the end of a six-week course of treatment and still maintain the same disease control as those receiving radiation to a larger area. But the dose of preventive radiation treatments given to the whole brain and spine over the six-week regimen cannot be reduced without reducing survival. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 10, 2021 Category: Cancer & Oncology Source Type: news
From the clinic to the lab, understanding medulloblastoma relies on molecular profiling
(St. Jude Children's Research Hospital) A pair of research papers from St. Jude Children's Research Hospital report on a medulloblastoma clinical trial that provides insights to guide treatment and shed light on relapsed disease. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 27, 2021 Category: Cancer & Oncology Source Type: news
Personalized drug screens could guide treatment for children with brain cancer
(Sanford Burnham Prebys Medical Discovery Institute) Scientists at Sanford Burnham Prebys Medical Discovery Institute, University of California San Diego School of Medicine and Hopp Children's Cancer Center Heidelberg (KiTZ) have demonstrated that personalized drug screens can be used to identify new therapeutic candidates for medulloblastoma. The approach measures the effectiveness of therapeutics using tumor cells obtained from a biopsy and can be performed in a few days--making it one of the quickest sources of information used in clinical decision-making. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2020 Category: International Medicine & Public Health Source Type: news
Cerebrospinal fluid as liquid biopsy for characterizing & policing of medulloblastoma
(Vall d'Hebron Institute of Oncology) Building on previous research led by Joan Seoane, Director of Translational Research at the Vall d'Hebron Institute of Oncology (VHIO) and ICREA Research Professor, latest findings from a proof-of-concept study published inNature Communications, show that the analysis of cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA), allows for the more precise characterization, molecular diagnosis (including subtyping and risk stratification), and real time tracking of medulloblastoma (MB) - the most prevalent malignant brain tumor in childhood. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 27, 2020 Category: International Medicine & Public Health Source Type: news
MUSC Hollings Cancer Center researcher receives award to study pediatric brain cancer
(Medical University of South Carolina) With this Rally Foundation grant, MUSC Hollings Cancer Center researcher Jezabel R. Blanco, Ph.D., will explore how the developmental pathway Sonic hedgehog gets activated in patients with mutations in the tumor suppressor P53 in medulloblastoma and the drivers of the stem cells of these tumors. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 5, 2020 Category: Cancer & Oncology Source Type: news
